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Genotype–Phenotype Correlation in Recessive Dystrophic
Epidermolysis Bullosa: When Missense Doesn’t Make Sense
To the Editor:
All forms of dystrophic epidermolysis bullosa (DEB) result
from mutations in the gene encoding type VII collagen,
COL7A1, the major component of anchoring fibrils at the
dermal–epidermal junction (Christiano et al, 1994). Approx-
imately 200 different pathogenic mutations have been re-
ported and, to some extent, a paradigm for genotype–
phenotype correlation has emerged. Typically, severe gen-
eralized forms of recessive DEB result from premature
termination codons on both COL7A1 alleles (Uitto and
Christiano, 1994), whereas autosomal dominant cases are
caused by heterozygous glycine substitutions within the
collagenous triple helix (Christiano et al, 1994). It is clear,
however, that the clinical diversity seen in both recessive
and dominant forms of DEB is mirrored by a spectrum of
mutations in COL7A1, with clinical heterogeneity partially
being explained through an accumulating database of other
missense, splice site, or insertion/deletion frameshift muta-
tions (Whittock et al, 1999).
In recessive DEB, the repertoire of mutations includes:
nonsense mutations, splice site mutations, internal dele-
tions or insertions, ‘‘silent’’ glycine substitutions within the
triple helix, and non-glycine missense mutations within the
triple helix or non-collagenous NC-2 domain (Whittock et al,
1999). We now report an example of a pathogenic missense
mutation within the NC-1 domain. The nucleotide substitu-
tion results in cryptic splicing and an in-frame deletion of 29
amino acids from the part of the protein with cartilage matrix
protein homology, thus providing clinicopathological evi-
dence for a new type of mutation in recessive DEB and
demonstrating the importance of this part of type VII col-
lagen in epidermal–dermal adhesion.
The proband is an 8-y-old Korean male with a history of
blisters and erosions at birth but only limited trauma-in-
duced blistering during infancy. But at the age of 7 y, there
was a worsening of blisters with development of milia and
scarring. There was never any history of skin itching. Phys-
ical examination revealed bullae (some of which were hem-
orrhagic), erosions, scars, and milia on his lower legs,
hands, feet, and pinnae. He also had dystrophic nails with
some loss of toenails (Fig 1A). Notably, the skin on his shins
was the most affected site (Fig 1B). No other family member
was affected and both parents are clinically normal. The
clinical features were suggestive of a mild form of recessive
DEB or possibly de novo dominant disease, including the
pretibial variant. Indirect immunofluorescence microscopy
of the affected individual’s skin using an anti-type VII col-
lagen monoclonal antibody (LH7.2; Fig 1C) (Heagerty et al,
1986) showed bright labeling at the dermal–epidermal junc-
tion that was of an intensity very similar to normal control
skin (Fig 1D). This finding is unhelpful in establishing the
precise diagnosis and in distinguishing between mild re-
cessive and de novo dominant DEB.
Following ethical approval, informed consent, and in
compliance with the Helsinki guidelines, DNA extraction
from peripheral blood samples from the patient and his
parents was performed using QIAamp DNA Blood Midi Kits
(Qiagen, Crawley, West Sussex, UK). PCR amplification of
the COL7A1 gene was performed, and heteroduplex anal-
ysis was carried out as described previously (Christiano
et al, 1997b). Any fragment with a different mobility to am-
plified control DNA was sequenced using dRhodamine dye
terminator technology on an ABI 310 capillary system (PE
Biosystems, Warrington, UK).
Sequencing of genomic DNA showed that the patient is
heterozygous for two nucleotide substitutions: 341G4T in
exon 3 and 5797C4T in exon 70, the former inherited from
the mother and the latter from the father (GenBank No.
L02870). The mutation 341G4T converts a glycine (GGG)
residue to valine (GTG) residue, and is designated G114V
(Fig 2A). The 5797C4T mutation changes arginine (CGA) to
a premature stop codon (TGA) and is designated R1933X
(Fig 2B). Thus, the affected individual is a compound he-
terozygote for the mutations G114V/R1933X in COL7A1.
The mutation R1933X has been reported once previously
in an individual with Hallopeau–Siemens recessive DEB
(compound heterozygote for R578X/R1933X) (Whittock
et al, 1999) but G114V is a new finding. The possibility
of this missense change being a non-pathogenic poly-
morphism was excluded by direct sequencing of 100
ethnically matched (Korean/Chinese/Japanese) control
chromosomes.
To assess the potential pathogenicity of the mutation
G114V, the genomic sequence was examined using the
Delila software package (Schneider, 1997a), which scans
genomic sequences with weight matrices for sites with
positive Ri (individual information content) values, and the
results were displayed using the Sequence Walker program
(Schneider, 1997b). The 341G4T nucleotide substitution,
located 86 nucleotides upstream from the exon 3 natural
donor, shows high semblance to the donor splice site con-
sensus (Zhang, 1998) and activates a new strong cryptic
site (Ri value increases from 0.0 to 8.2 bits) at this position
(Fig 2C and D), whereas the natural donor site remainsAbbreviation: DEB, dystrophic epidermolysis bullosa
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unchanged at 6.6 bits (Fig 2E). This change is predicted to
result in aberrant splicing with removal of the last 87 nuc-
leotides of exon 3, as well as some residual splicing at the
natural donor splice site.
Following informed consent, extraction of total RNA from
skin biopsies of the proband, mother, and control was per-
formed using Qiagen RNeasy Mini Kits (Qiagen) with sub-
sequent reverse transcription using ABgene Reverse-iT 1st
Strand Synthesis Kit (ABgene House, Epsom, Surrey, UK).
The following sets of exonic primers were used to amplify
and sequence COL7A1 complementary DNA (cDNA) in the
region of the mutation G114V: sense primer 50-AT-
GACCCACGGACAGAGTTC-30 and anti-sense primer 50-
AACTCGCTTCAGCTCCTCAG-30 (PCR product 302 base
pairs; nucleotide positions 257–558). The annealing tem-
perature used was 551C. Agarose gel electrophoresis of the
amplified PCR products showed two bands in the pro-
band’s and mother’s samples compared with a single band
in the control (Fig 3A). Direct sequencing of the smaller
band (proband and mother) confirmed the anticipated 87-
bp deletion in exon 3, corresponding to nucleotides 340–
426 (340del87) (Fig 3B). This is predicted to result in an in-
frame deletion of 29 amino acids from the NC-1 domain of
type VII collagen. This deletion occurs within the region of
cartilage matrix protein homology and is upstream from the
nine fibronectin III-like repeats, within which the epitope for
the LH7.2 antibody occurs (Tanaka et al, 1994) (Fig 3C). This
finding helps explain the ‘‘normal’’ intensity anti-type VII
collagen immunostaining, as well as demonstrating, in a
Figure 1
Clinicopathological assessment is consistent with either localized
recessive dystrophic epidermolysis bullosa or de novo dominant
disease. The clinical features include (A) dystrophic or rudimentary
toenails and (B) blisters, erosions, and inflammatory papules on the
shins. Indirect immunofluorescent staining with LH7.2 monoclonal an-
tibody (NC-1 domain of type VII collagen) shows bright linear labeling at
the dermal–epidermal junction in the patient’s skin (C) of intensity and
distribution similar to normal control skin (D). Scale bar¼ 40 mm.
Figure2
Nucleotide sequencing of the patient’s genomic DNA reveals com-
pound heterozygosity for two single nucleotide substitutions in
COL7A1. (A) There is a heterozygous 341G4T transition in exon 3
(maternally inherited), which is predicted to change a glycine residue to
valine (G114V). (B) There is also a heterozygous 5797C4T transition in
exon 70 (paternally inherited), which is predicted to change an arginine
residue to a stop codon (R1933X). The mutation 341G4T, however, is
also predicted to activate a new strong cryptic site, with the Ri value
increasing from 0.0 bits (C) to 8.2 bits (D) at this position, whereas the
natural donor site remains unchanged at 6.6 bits (E). This suggests
cryptic splicing induced by the substitution 341G4T. No such changes
were evident in assessing 5797C4T.
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patient with DEB, the functional role of the cartilage matrix
protein homology region in dermal–epidermal adhesion.
The possible effects of the paternal nonsense mutation
on aberrant splicing were also examined using the same
approach. The nucleotide substitution 5797C4T, which is
located 25 nucleotides upstream from the exon 70 natural
donor, shows an increase in Ri value from 1.7 to 5.8 bits at
this position, whereas the natural donor site remains un-
changed at 8.7 bits. Although the cryptic site created by this
substitution is a legitimate site, it is 2.9 bits weaker than
the natural site, which would correspond to an 8-fold
(2DRi¼ 22.9) difference in splicing, assuming minimal con-
version of information to energy dissipated (Rogan et al,
1998). Even though this site is presumably scanned first, the
thermodynamic difference is so marked that it cannot com-
pete for binding to the U2 spliceosome. Indeed, RT-PCR
amplification across the site of the mutation R1933X using
the proband’s cDNA did not disclose any evidence of cryp-
tic splicing (data not shown).
Our study has identified the pathogenic relevance of a
particular nucleotide substitution in COL7A1, 341C4T, in
inducing cryptic splicing within the NC-1 domain. It is likely
that this previously unreported phenomenon in type VII col-
lagen may also account for the molecular pathology in a
number of other patients with recessive DEB. Indeed, a
retrospective analysis of our non-Hallopeau Siemens gen-
eralized RDEB patient mutation database has identified
some similar sequence variants in the NC-1 domain that
may also potentially lead to cryptic splicing. These include
245T4G (V82G) in exon 2 and 3359G4A (R1120K) in exon
25. But there is no evidence that such a phenomenon may
also occur at other sites.
Specifically, from the collated COL7A1 mutation dat-
abases, a small number of potential pathogenic (non-
glycine) missense mutations have been reported: these in-
clude R1772W (exon 61); Q1924P (exon 70); R2002C,
R2008C, and R2008G (all exon 73); R2063G and R2063W
(exon 74); and R2791W, M2798K (both exon 113). Of these
mutations, R2008G and R2063G result in new glycine res-
idues within the triple helix and may therefore disrupt the
structure of the collagenous triple helix. Q1924P occurs
within a consensus splice site, but it is predicted to have
only a limited effect on splicing (Ri value reduces from 10.9
to 8.9 bits). Of the remainder, analysis with the Delila soft-
ware package predicts no cryptic splicing.
Mutations resulting in aberrant splicing account for at
least 15% of all DEB mutations, and occur in both recessive
and dominant disease (Whittock et al, 1999). Over 30 single
nucleotide substitutions within consensus sites (mostly at
the þ1 or 1 position) have been described, although RNA
analysis is usually lacking. It has mostly been assumed that
such mutations result in exon skipping but, even in the ab-
sence of available RNA, it is now evident that the splicing
software can add to genotype–phenotype understanding.
For example, the mutation IVS35-1G4C has been reported
in a three-generation family with transient bullous disease of
the newborn (Christiano et al, 1997a), an autosomal dom-
inant condition that ameliorates with increasing age. Anal-
ysis using the Delila software reveals that this mutation
results in a ‘‘leaky’’ acceptor splice site (Ri value reduced
from 11.8 to 4.5), thus predicting both in-frame skipping of
exon 36 (78 bp) and normal splicing. It is plausible, there-
fore, that relative differences in these two possible splice
choices at different ages (neonate versus adult) account for
the clinical pattern of this family’s DEB. To add to the molec-
ular complexity of splicing anomalies in other forms of dom-
inant and recessive DEB, it has been shown that certain
exonic sequences outside consensus splice sites also may
influence splicing and a few examples of internal deletions (up
to 28 bp) in exons 73 or 87 of COL7A1 have been reported
(Cserhalmi-Friedman et al, 1998; Sakuntabhai et al, 1998).
Overall, this study further expands the spectrum of dif-
ferent types of pathogenic mutations in COL7A1 in individ-
uals with recessive DEB, as well as highlighting the subtle
but consequential effects of cryptic splicing in this inherited
skin disorder. The study also illustrates the utility of com-
Figure 3
Direct sequencing of complementary DNA (cDNA) from the pa-
tient’s and mother’s skin confirms cryptic splicing in exon 3. (A)
PCR of cDNA between nucleotide positions 257 and 558 reveals a
single 302 bp band in a control (C) and two bands in the proband (Pt)
and mother (M), one of which is 302 bp and the other 215 bp, i.e., 87 bp
shorter. (B) Direct sequencing of the lower band reveals an 87 bp de-
letion between nucleotides 340 and 426. (C) Schematic diagram of the
NC-1 domain of COL7A1 messenger RNA showing the position of the
29 amino acid deletion within the CMP domain, upstream from the
epitope for the LH7.2 antibody in the middle of the FN III-like repeats.
SP, signal peptide; CMP, domain with homology to cartilage matrix
protein; FN III, fibronectin-type III-like motifs; VWF-A, von Willebrand
factor-type A-like domain; C/P, cysteine- and proline-rich domain
(Christiano et al, 1992).
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putational tools that can accurately predict cryptic splicing,
such as Automated Splice Site Analyses (https://splice.
cmh.edu/cgi-bin/protected/menu.cgi?menu.html) or Splice
Site Prediction by Neural Network (http://www.fruitfly.org/
seq_tools/splice.html).
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